AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Sensus Healthcare: HC Wainwright & Co. reiterates the 'Buy' Rating, The Target Price is $12
ByAinvest
Friday, Apr 4, 2025 2:00 pm ET1min read
HC Wainwright & Co. reiterates 'Buy' rating on Sensus Healthcare(SRTS).
The target price is unchanged and still at 12 .
[Recent Rating]
| Date | Agency | Change | Rating | Rating （previously） | Target Price | Target Price（previously） |
|---|---|---|---|---|---|---|
| 2025-04-04 | HC Wainwright & Co. | Reiterates | Buy | Buy | $12 | $12 |
| 2025-03-11 | Lake Street | Maintains | Buy | Buy | $13 | $18 |
[Recent Earning Results] Sensus Healthcare posted the Q4 of its 2024 financial results on 3/5/2025, reporting total revenue of USD 41.81 million for the year, up 71.31% from USD 24.41 million year over year, reporting net income of USD 6.65 million for the year, up 1270.52% from USD 0.49 million year over year.
[Company Profile] Sensus Healthcare, Inc., a Delaware limited liability company, was formed on May 7, 2010. The company is a medical device company committed to providing highly effective, non-invasive, and cost-effective treatments for both oncological and non-oncological skin conditions. The Company uses a proprietary low-energy X-ray technology known as superficial radiation therapy (“SRT”), which is based on over a decade of dedicated research and development, and has successfully incorporated SRT into a portfolio of treatment devices: the SRT-100TM, SRT-100+TM and SRT-100 VisionTM. To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in hundreds of thousands of patients around the world.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet